Author | Year | Study design | Patients (n) | Protocol (n patients) | Results |
---|---|---|---|---|---|
Patil et al. [16] | 2015 | phase II | 110 | celecoxib + methotrexate (57); cisplatinum (53) | OS 101 vs 66 days*; PFS 249 vs 152 days* |
Pai et al. [17] | 2013 | retrospective | 64 | celecoxib + methotrexate (32); no MC (32) | 2-year DFS 94.6 % vs 75.4 %* |
Penel et al. [18] | 2010 | randomised | 88 | cyclophosphamide (44); megestrol acetate (44) | 2-month PFS 20.5 % vs 9 %; median OS 195 vs 144 days |